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The superfamily of TGF- encompasses two 
major subfamilies: the TGF- family and the 
bone morphogenic protein (BMP)/growth dif-
ferentiation  factor  (GDF)  subfamily  (Shi  and 
Massagué, 2003). TGF- family members have 
pleiotropic effects on cell cycle (proliferation, dif-
ferentiation,  and  apoptosis),  inflammation,  and 
cellular motility and adhesion (Massagué, 1998; 
Massagué et al., 2000). Generally TGF- mem-
bers interact with the common membrane-bound 
TGFRII (TGF- receptor 2), which conse-
quently forms oligomers with TGFR1, leading 
to SMAD-dependent signaling (Kingsley, 1994). 
After nuclear translocation, SMAD complexes   
interact with coactivators to induce transcrip-
tional activation of several target genes (Hogan, 
1996; Liu and Niswander, 2005). Members of the 
BMP/GDF family interact with two serine/thre-
onine kinase receptors ( BMPR1 and BMPRII ), 
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Growth differentiation factor (GDF) 15 is a member of the transforming growth factor   
(TGF-) superfamily, which operates in acute phase responses through a currently un-
known receptor. Elevated GDF-15 serum levels were recently identified as a risk factor for 
acute coronary syndromes. We show that GDF-15 expression is up-regulated as disease 
progresses in murine atherosclerosis and primarily colocalizes with plaque macrophages. 
Hematopoietic GDF-15 deficiency in low density lipoprotein receptor/ mice led to im-
paired initial lesion formation and increased collagen in later lesions. Although lesion 
burden in GDF-15/ chimeras was unaltered, plaques had reduced macrophage infiltrates 
and decreased necrotic core formation, all features of improved plaque stability. In vitro 
studies pointed to a TGFRII-dependent regulatory role of GDF-15 in cell death regulation. 
Importantly, GDF-15/ macrophages displayed reduced CCR2 expression, whereas GDF-15 
promoted macrophage chemotaxis in a strictly CCR2- and TGFRII-dependent manner, a 
phenomenon which was not observed in G protein–coupled receptor kinase 2+/ macro-
phages. In conclusion, GDF-15 deletion has a beneficial effect both in early and later 
atherosclerosis by inhibition of CCR2-mediated chemotaxis and by modulating cell death. 
Our study is the first to identify GDF-15 as an acute phase modifier of CCR2/TGFRII-
dependent inflammatory responses to vascular injury.
© 2011 de Jager et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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RESULTS AND DISCUSSION
GDF-15 deficiency attenuates early atherogenesis  
and improves plaque stability
GDF-15  is  a  distant  member  of  the TGF-  superfamily 
(Bootcov et al., 1997), which is well known for its pleiotropic 
mode of action. Allelic GDF-15 mutations have been shown 
to  associate  with  inflammatory  disorders  such  as  severe 
treatment-resistant chronic rheumatoid arthritis (Brown et al., 
2007). Moreover, elevated GDF-15 serum levels are an inde-
pendent risk factor for acute coronary syndromes (Wollert   
et al., 2007), pointing to a proatherogenic role of this cyto-
kine. We show that GDF-15 staining mainly colocalized with 
subendothelial macrophages (Fig. 1 E), which concurs with 
earlier observations (Schlittenhardt et al., 2004). Moreover, 
GDF-15 expression is significantly higher (1.3-fold induced, 
P = 0.0007) in acute stages of human plaque rupture (un-
stable angina pectoris) than in advanced stable lesions (stable   
angina pectoris). GDF-15 was up-regulated in murine ath-
erosclerotic lesions during disease progression in a pattern 
similar to that of the macrophage marker CD68, whereas no 
similarity  was  found  with  smoothelin  (vascular  smooth   
muscle cell marker) or PECAM-1 (endothelial cell marker; 
Fig. 1, A–D). It should, however, be noted that marker expres-
sion only reflects gross plaque expression and does not allow 
us to distinguish regulation of GDF-15 in individual cell 
types. Immunohistochemistry showed clear expression of   
GDF-15 in murine atherosclerotic lesions (Fig. 1 F), mainly 
confined  to  macrophage  rich  regions  and  the  plaque   
shoulder. These findings led us to investigate the role of   
inducing a signal transduction pathway very similar to that of   
the TGF- family (Hogan, 1996; Liu and Niswander, 2005). 
However, BMPs were shown to have affinity for the classical 
TGF- receptors and, most notably, TGFRI as well.
GDF-15, also known as MIC-1 (macrophage inhibitory 
cytokine 1), is a distant member of the subfamily of BMPs 
(Bootcov et al., 1997). GDF-15 has alleged antiinflammatory 
activity through a currently unknown receptor. It is weakly 
expressed under normal conditions (Bootcov et al., 1997) but 
is  sharply  up-regulated  under  conditions  of  inflammation 
(Hsiao et al., 2000), acting as an autocrine regulator of macro-
phage activation (Bootcov et al., 1997). In addition to its   
effects on macrophages, GDF-15 was also identified as a down-
stream target of p53, suggesting a role in injury response to 
DNA damage and in cancer.
GDF-15, both tissue-derived and circulating, appeared 
to be cardio-protective in mouse models for myocardial in-
farction  and  heart  failure  (Kempf  et  al.,  2006;  Xu  et  al., 
2006).  Paradoxically,  elevated  GDF-15  serum  levels  were 
shown to be an independent risk factor for early chest pain 
(Bouzas-Mosquera et al., 2008; Eggers et al., 2008) and acute 
coronary syndromes (Wollert et al., 2007; Khan et al., 2009). 
In this study, we have addressed the potential involvement of 
GDF-15 in atherogenesis, the major cause of acute cardio-
vascular syndromes. In this paper, we demonstrate that hemato-
poietic GDF-15 deficiency attenuates early lesion formation 
by reducing CCR2 chemotaxis and improves atherosclerotic 
plaque stability by enhancing collagen deposition and de-
creasing necrotic core expansion.
Figure 1.  GDF-15 is progressively expressed in atherosclerotic lesions in a pattern similar to that of macrophages. (A–D) Temporal ex-
pression of GDF-15 (A), CD68 (B), Smoothelin (C) and PECAM-1 (D) during atherogenesis was assessed by whole genome microarray. Values are 
expressed as fold induction compared with time point zero. The experiment was performed twice, with n = 3 (each containing pooled plaque ma-
terial of three mice) per time point. *, P < 0.05; ***, P < 0.001, compared with the 0-wk timepoint. Error bars are depicted as SEM. (E and F) Immuno-
histochemistry for GDF-15 in human (E) and murine (F) atherosclerotic lesions. Arrows represent intimal cells (based on nuclear staining) that 
express GDF-15.JEM VOL. 208, February 14, 2011  219
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respectively;  P  =  0.25;  Fig.  2  B). 
GDF-15  deficiency  apparently  has   
a more profound impact on plaque 
initiation than on progression.
Despite the similar plaque size, we 
did notice striking differences in plaque 
composition  between  GDF-15/  
and WT chimeras at the 12-wk time 
point. Plaque cellularity was signifi-
cantly decreased in GDF-15/ chi-
meras (1.33 ± 0.11 vs. 1.94 ± 0.14 × 
103 cells/µm2 for WT; P = 0.003). This 
decrease was partially attributable to a 
decrease in plaque macrophages (30.7 ± 
5.6 vs. 45.6 ± 6.1% for WT; P = 0.04; 
Fig. 2 C). Next to a decreased inflamma-
tory  status,  plaques  of  GDF-15/ 
chimeras displayed more pronounced 
collagen deposition (18.2 ± 1.5 in GDF-15/ vs. 11.4 ± 
2.5% in WT; P = 0.04; Fig. 2 D). These beneficial effects of 
leukocyte GDF-15 deficiency on plaque stability are in sharp 
contrast with that of other TGF- family members such as   
activin-A (Engelse et al., 1999) and  TGF-1, where neutraliza-
tion resulted in accelerated atherosclerosis and plaque destabi-
lization (Mallat et al., 2001; Lutgens et al., 2002). Similarly, 
specific disruption of TGFRII signaling aggravated athero-
genesis and, again, shifted lesion composition toward a more 
unstable phenotype (Lutgens et al., 2002). The compositional 
changes observed in more advanced lesions likely reflect a 
decreased inflammatory status in plaques of GDF-15/ chi-
meras resulting in a stabilized plaque phenotype. However, we 
cannot proclaim that the long-term composition will remain 
stable or perhaps progress into a more unstable phenotype 
during further lesion progression.
GDF-15 colocalizes with oxidized low density lipopro-
tein (ox-LDL) in the atherosclerotic plaque and contributes 
to ox-LDL induced oxidative stress and subsequent apoptosis 
(Schlittenhardt et al., 2004). In keeping with these findings, 
leukocyte GDF-15 deficiency in atherogenesis by use of a 
bone marrow transplantion.
Hematopoietic  GDF-15  deficiency  influenced  neither 
body weight nor total cholesterol levels throughout the ex-
periment (unpublished data). GDF-15 expression in peritoneal 
macrophages and in lymphoid organs of GDF-15/ chimeras 
was almost completely blunted, whereas GDF-15 expression in 
liver was reduced by a significant 60% (Table S1). Given the 
substantial residual hepatic GDF-15 expression, we cannot 
fully exclude compensatory up-regulation by nonhematopoi-
etic sources of GDF-15 under steady-state conditions. How-
ever, as GDF-15 is mainly operational upon focal tissue injury 
such as in atherosclerotic tissue, we believe nonhematopoietic 
GDF-15 will hardly contribute to the atherogenic response.
After recovery, mice were put on a Western-type diet for 
4 and 12 wk. Early lesion development (4 wk) was strongly 
impaired in GDF-15/ chimeras (15.8 ± 2.8 in GDF-15/ 
vs. 51.5 ± 11.0 × 103 µm2 in WT chimeras; P = 0.02; Fig. 2 A), 
whereas at week 12 plaque burden in WT and GDF-15/ chi-
meras was almost equalized (232 ± 33 and 174 ± 35 × 103 µm2, 
Figure 2.  Effects of GDF-15 deficiency 
on atherogenesis and plaque cellularity. 
Irradiated LDLr/ recipients were reconsti-
tuted with WT or GDF-15/ bone marrow.  
(A and B) Plaque size after 4 wk (A) or 12 wk 
(B; representative pictures in E and F).  
(C) Macrophages were stained with –MoMa-2 
and depicted as percentage of MoMa-2+ cells 
among total plaque area (representative  
pictures in G). (D) Collagen was visualized by 
Masson’s trichrome staining and depicted as 
percentage of collagen among total plaque 
area (representative pictures in H). *, P < 0.05, 
compared with WT controls. n = 9 animals 
per group. The experiment was independently 
performed two times. Error bars are depicted 
as SEM.220 GDF-15 affects plaque stability | de Jager et al.
that defective clearance of apoptotic cells by macrophages 
leads to increased necrotic core formation and inflammation 
in atherosclerotic lesions (Ait-Oufella et al., 2008; Thorp et al., 
2008), the minor effect on phagocytosis we observe is not 
likely to influence plaque inflammation and necrosis.
Hematopoietic GDF-15 deficiency does not alter monocyte 
differentiation and stromal release
A second striking observation was the reduced presence of   
macrophages in plaques of GDF-15/ chimeras. To establish if 
this was a direct consequence of disturbed monocyte differen-
tiation  in  these  chimeras,  we  assessed  both  circulating  and   
peritoneal monocyte numbers, which were both unaltered in 
the GDF-15/ chimeras (P = 0.8 and P = 0.1; Fig. S2, A and B). 
As CCR2 is a crucial chemokine receptor for monocyte recruit-
ment to early atherosclerotic lesions, we assessed the number of 
CCR2-expressing circulating monocytes as well. In agreement 
with the earlier observations, CCR2+ monocyte numbers were 
unaltered (P = 0.5; Fig. S2 C). To exclude the possibility that   
the impaired atherogenic response in GDF-15/ chimeras is 
related to altered myeloid differentiation, we screened bone 
marrow cells by flow cytometry. CD11b+ monocyte numbers   
in stroma of GDF-15/ were unchanged (P = 0.3; Fig. S2 D) 
and similar results were obtained for the CCR2+ monocyte 
we now demonstrate that the necrotic core area was signifi-
cantly smaller in GDF-15/ chimeras (13.3 ± 4.2 vs. 29.1 ± 
4.2% in WT; P = 0.02; Fig. 3 A), as was the rate of intimal apop-
tosis (1.1 ± 0.35 vs. 2.3 ± 0.35% in WT; P = 0.03; Fig. 3 B).   
To further elaborate on this, we assessed whether GDF-15 
was able to influence macrophage death in vitro. Exposure of 
RAW 264.7 macrophages to recombinant GDF-15 promoted   
S-to-G2 transition and did so in a TGFRII-dependent man-
ner (Fig. 3 C). GDF-15 did not induce apoptosis of both WT   
and GDF-15/ macrophages, whereas ox-LDL and campto-
thecin (CPT) did so robustly (Fig. 3 D and Fig. S1 A).   
Ox-LDL robustly induced necrosis of WT macrophages, 
whereas GDF-15/ macrophage appeared less susceptible to 
ox-LDL–induced necrosis (Fig. 3 E). The apoptosis inducer 
CPT did not influence necrosis (Fig. S1 B). Although we were 
unable to detect a direct effect of GDF-15 on macrophage 
apoptosis, our data suggest that GDF-15/ macrophages are 
less susceptible to ox-LDL–induced apoptosis and necrosis 
(Fig. 3, D and E). Additionally, GDF-15 might have indirectly 
affected apoptotic cell number within the atherosclerotic 
plaque by affecting phagocytosis of apoptotic cells. GDF-15/ 
macrophages  displayed  a  diminished  rather  than  increased 
phagocytotic capacity (24% decreased; 20.1 ± 0.4 in GDF-15/ 
vs. 26.3 ± 1.8% in WT macrophages). Although it is believed 
Figure 3.  Effects of GDF-15 deficiency on plaque stability. (A) Necrotic core size depicted as percentage among total plaque area. (B) Cellular 
apoptosis was visualized by TUNEL staining and depicted as TUNEL+ cells among all mononuclear cells (including representative pictures) in week-12 
plaques. *, P < 0.05, compared with WT controls (n = 9 per group). Arrows indicate TUNEL-positive nuclei. (C) S/G2 phase arrest (depicted as percentage  
among total cells) in RAW 264.7 macrophages after treatment with 10 ng/ml GDF-15 (gray bars) and 100 ng/ml -TGFRII (black bars). **, P < 0.01;  
***, P < 0.001, compared with untreated controls (white bars); #, P < 0.001, compared with GDF-15 treatment. Studies were performed four times per 
condition and repeated in three separate experiments. (D and E) Rate of macrophage apoptosis (D; percentage annexin V+/PI cells) and necrosis (E; per-
centage annexin V+/PI+ cells) after treatment with 10 ng/ml GDF-15 or 50 µg/ml ox-LDL in both GDF-15/ (black bars) and WT (white bars) macrophages.   
**, P < 0.01; ***, P < 0.001 when compared with control; #, P < 0.05, compared with WT. (F) Phagocytosis capacity in WT (white bars) and GDF-15/ 
(black bars) macrophages. *, P < 0.05 when compared with WT. Bone marrow–derived macrophages from WT and GDF-15 chimeras were pooled and  
used for apoptosis and phagocytosis assays. Each experiment was performed four times. Error bars are depicted as SEM.JEM VOL. 208, February 14, 2011  221
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for mRNA expression of CCR2, MCP-1, IFN-, and TGF-. 
Interestingly GDF-15/ macrophages displayed decreased 
CCR2 expression (Fig. 4 A), whereas expression of its ligand 
MCP-1 was not altered (Fig. 4 B). This finding further substan-
tiates the notion that GDF-15 mainly acts focally, as systemic 
inhibition of CCR2 signaling was shown to increase circulating 
MCP-1 levels (Vergunst et al., 2008). Additionally, membrane-
expressed CCR2, but not CCR5, was up-regulated on perito-
neal leukocytes upon GDF-15 exposure (Fig. S3, A and B). Basal 
expression of the proinflammatory cytokine IFN- (Fig. 4 C) 
was  significantly  down-regulated  in  GDF-15/  macro-
phages, whereas expression of TGF- was increased (Fig. 4 D), 
reflective of antiinflammatory properties of GDF-15/ macro-
phages. In agreement with the latter, ex vivo stimulation of 
peritoneal GDF-15/ macrophages with the TLR-4 ligand 
subset (P = 0.5; Fig. S2 E). GDF-15 deficiency did not skew 
monocyte  polarization  (Fig.  S2  F)  toward  the  Ly6Chigh 
CCR2+ CX3CR1mid phenotype, the main subset to accu-
mulate in atherosclerotic plaques in early atherogenesis (Tacke   
et al., 2007). Collectively, our data suggest that stromal reten-
tion of CCR2+ monocytes or monocyte differentiation is not   
notably altered in GDF-15/ chimeric mice.
GDF-15–deficient macrophages display  
decreased CCR2 expression, accompanied by modified 
inflammatory characteristics
To further assess the effect of GDF-15 deficiency on macro-
phage characteristics, we quantified the expression of pro- and 
antiinflammatory  mediators  in  macrophages  from WT  and 
GDF-15/ chimeras. Peritoneal macrophages were analyzed 
Figure 4.  Pro- and antiinflammatory mediators in GDF-15/ cells and chimeras. (A–D) Relative mRNA expression of CCR2 (A), MCP-1 (B), IFN- 
(C), and TGF- (D) in WT (white bars) and GDF-15/ (black bars) macrophages. Values are expressed relative to average expression of GAPDH and HPRT 
reference genes. (E and F) MCP-1 (E) and TGF- (F) production in WT (white bars) and GDF-15/ (black bars) macrophages after LPS treatment. (G) Basal  
levels of MCP-1 (white bars) and TGF- (black bars) in WT and GDF-15/ chimeras after 4 wk of Western type diet. (H) Relative mRNA expression of  
PAI-1 and MCP-1 in response to 10 ng/ml GDF-15– and 15 ng/ml TGF-1–treated WT macrophages. (I) Relative MCP-1 mRNA expression after SMAD-3  
inhibition (SIS3; 3 µM) and -TGFRI and -TGFRII treatment (100 ng/ml) in WT macrophages. Bone marrow–derived macrophages from WT and  
GDF-15 were pooled and used for RNA expression. Each experiment was done four times. *, P < 0.05; **, P < 0.01. Error bars are depicted as SEM.222 GDF-15 affects plaque stability | de Jager et al.
may  well  be  re-
lated to an impaired   
mobility,  possibly 
via  modulation  of 
CCR2  function,  as   
we  observed  de-
creased  CCR2  ex-
pression on GDF-15/ macrophages. This notion derives 
further support from the fact that, like MCP-1 (Guo et al., 
2003, 2005), GDF-15 deficiency also seems to preferentially 
affect  plaque  initiation.  Indeed,  basal  GDF-15/  macro-
phage mobility was significantly lower than that of WT cells   
(Fig. S3 C). Conversely, GDF-15/ cells displayed an equally 
potent  migratory  response  toward  GDF-15,  MCP-1,  or 
fMLP as WT macrophages (Fig. 5 A). Interestingly, GDF-15–
induced migration is depended on TGFRII and SMAD-3 
signaling, whereas blockade of TGFRI slightly potentiates 
GDF-15–induced migration in WT macrophages (Fig. 5 B). 
GDF-15 was almost equally effective at promoting macro-
phage migration as MCP-1 in a chemotaxis assay (Fig. 5 C). 
Co-stimulation of macrophages with GDF-15 and MCP-1 
did not lead to an augmented response, which is suggestive 
of convergent migratory pathways (Fig. 5 C). To dissect in-
terference of GDF-15 with CCR2 chemotaxis, we studied 
the chemotactic response of CCR1-, CCR2-, and CCR5-
deficient macrophages to GDF-15. Surprisingly, GDF-15 was   
unable to induce CCR2/ cell migration, whereas GDF-15– 
induced chemotaxis of CCR1/ and CCR5/ macro-
phages was unaltered (Fig. 5 D). Although these findings point 
to a direct interaction of GDF-15 with chemokine recep-
tor CCR2 function, MCP-1 release by WT and GDF-15– 
deficient macrophages in response to LPS was essentially   
similar. This suggests that GDF-15–induced macrophage mo-
bility may, at least in part, be exerted by a modulating effect 
of this cytokine on CCR2 responsiveness.
The activity of most G protein–coupled receptors, includ-
ing CCR2, is regulated not only at the mRNA and protein 
LPS did not alter MCP-1 production (Fig. 4 E), but it did result 
in increased production of TGF- compared with stimulated 
WT macrophages (Fig. 4 F). Moreover MCP-1 and TGF-  
serum levels did not differ between GDF-15 and WT chimeras 
(Fig. 4 G), suggesting that GDF-15 may exert its immuno-
modulatory effects not at a systemic but at a focal level within 
the plaque. The decreased inflammatory status of GDF-15/ 
macrophages findings nicely reflect the effects on plaque   
stability we observed in the GDF-15/ chimeras. The anti-
inflammatory effects of GDF-15/ macrophages directly alter 
intimal macrophage accumulation, apoptosis/necrosis, and col-
lagen production, consequently resulting in distinct composi-
tional differences of the atherosclerotic plaques (Fig. 2).
GDF-15, but not TGF-, specifically up-regulates  
MCP-1 expression
As a TGF- family member, GDF-15 is likely to signal through 
TGFRII. Indeed recombinant GDF-15 and TGF-1 were 
both seen to induce the expression of plasminogen activator 
inhibitor 1, an established TGF- responsive gene, in RAW   
264.7 macrophages (Fig. 4 H). This implies that signal transduc-
tion cascades for both cytokines partly overlap. Unlike TGF-1, 
however, GDF-15 did induce MCP-1 expression (Fig. 4 B). 
This effect could be prevented by coincubation with a SMAD3 
inhibitor, implicating this adaptor protein in GDF-15 signaling 
(Fig. 4 I). Blockade of TGFRII, but not TGFRI/ALK5, ab-
rogated the GDF-15–elicited MCP-1 response (Fig. 4 I). This 
suggests that GDF-15 signaling in macrophages does not re-
quire TGFRI; however, we cannot exclude the involvement 
of other ALK family members. These data demonstrate that   
although TGF- and GDF-15 both signal via TGFRII, only 
GDF-15 was capable of inducing MCP-1.
Hematopoietic GDF-15 deficiency attenuates  
MCP-1–directed macrophage migration
The findings in the previous section suggest that the reduced 
macrophage accumulation in plaques of GDF-15/ chimeras   
Figure 5.  GDF-15 sensitizes CCR2-medi-
ated chemotactic response. (A) Migration 
response of WT (white bars) and GDF-15/ 
(black bars) macrophages to GDF-15, MCP-1, 
and fMLP. (B) Migratory response of WT (white 
bars) and GDF-15/ (black bars) macro-
phages to GDF-15 after treatment with  
-TGFRI, -TGFRII, and SMAD-3 inhibition. 
(C) Migratory response of WT peritoneal macro-
phages after combined GDF-15 and MCP-1 
treatment. (D) Macrophage migration toward 
GDF-15 in WT and CCR1-, CCR2-, and CCR5-
deficient macrophages. (E) Relative GRK-2 
mRNA expression in WT bone marrow–derived 
macrophages after exposure to GDF-15.  
(F) Migratory response toward GDF-15 and 
MCP-1 of GRK-2+/ macrophages. *, P < 0.05; 
**, P < 0.01; ***, P < 0.001, when compared 
with control; and #, P < 0.05; ##, P < 0.01;  
###, P < 0.001, when compared with GDF-15. 
Migration and mRNA expression assays were 
performed with pooled bone marrow–derived 
macrophages from WT and GDF-15. Each 
experiment was repeated six (migration)  
and four (mRNA) times. Error bars are de-
picted as SEM.JEM VOL. 208, February 14, 2011  223
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marrow cells by tail vein injection and were allowed to recover for 6 wk. 
Drinking water was supplied with antibiotics (83 mg/liter ciprofloxacin 
and 67 mg/liter polymyxin B sulfate) and 6.5 g/liter sucrose and provided 
ad libitum. Animals were placed on a Western-type diet containing 0.25% 
cholesterol and 15% cacao butter (SDS) diet for 4 and 12 wk and subse-
quently sacrificed.
Histological  analysis.  10-µm  cryostat  sections  of  the  aortic  root   
were  collected  and  stained  with  Oil-red-O  to  determine  lesion  size. 
Macrophages were visualized immunohistochemically with an antibody 
directed against a macrophage-specific antigen (MOMA-2, monoclonal 
rat IgG2b, dilution 1:50; AbD Serotec). Goat anti–rat IgG-AP (dilution   
1:100; Sigma-Aldrich) was used as secondary antibody and NBT-BCIP   
(Dako)  as  enzyme  substrates.  Masson’s  trichrome  staining  (Sigma-Aldrich)   
was  used  to  visualize  collagen  (blue  staining).  Cellular  apoptosis  was   
visualized  using  a  terminal  deoxytransferase  dUTP  nick-end  labeling 
(TUNEL) kit (Roche). Apoptotic nuclei were scored manually. Intimal 
necrosis  was  determined  by  assessment  of  necrotic  area  in TUNEL-
stained sections. Histological analysis was performed by an independent 
operator (SdJ).
Flow cytometry. Peritoneal leukocytes were harvested by peritoneal cavity 
lavage with PBS. Cells were centrifuged for 5 min at 1,500 rpm and resus-
pended in lysis buffer to remove residual erythrocytes. Cell suspensions were 
incubated with 1% normal mouse serum in PBS and stained for the surface 
markers F4/80 antigen, CD11b (eBioscience), Ly6C (BD), and CCR2 (clone 
E68; Abcam) at a concentration of 0.25 µg of antibody per 200,000 cells. 
Subsequently cells were subjected to flow cytometric analysis (FACSCalibur; 
BD). FACS data were analyzed with CellQuest software (BD).
Cell cycle. Serum-deprived RAW 264.7 macrophages were stimulated with 
10 ng/ml of recombinant GDF-15 and 100 ng/ml of recombinant mouse 
TGFRII/mouse FC (R&D Systems) for 6, 12, and 24 h. Cells were washed 
twice in PBS and fixed in ice-cold 70% ethanol for 24 h. Cells were then 
washed twice in HBSS and resuspended in PBS containing 0.1 mM EDTA, 
0.1% Triton X-100, 50 µg/ml RNase A, and 50 µg/ml propidium iodide (PI). 
After incubation at room temperature for 30 min, cells were analyzed for cell 
cycle distribution with an EPICS XL flow cytometer (Beckman Coulter) 
and EXPO32 software (Beckman Coulter).
Apoptosis  assay. Cellular apoptosis was measured using an Annexin V-
FITC/PI  staining  kit  (Invitrogen).  Serum-deprived  cells  were  stimulated 
with 10 ng/ml of recombinant GDF-15, 50 µg/ml ox-LDL, and 0.5 and   
1 µM CPT (Sigma-Aldrich).
Phagocytosis  assay. After induction of apoptosis of Jurkat T cells with   
1 µM CPT, cells were washed two times in PBS and then labeled with 1 µg/ml 
CellTracker red (Invitrogen) for 1 h at 37°C at a cell concentration of 1 × 
106 cells/ml. Fluorescently labeled apoptotic cells and macrophages were 
washed three times with PBS. Macrophages were incubated for 3 h at 37°C 
with labeled apoptotic cells (ratio of 1:5; RPMI [Invitrogen] supplemented 
with 10% FCS and 15% LCM). The wells were then washed two times with 
PBS, to remove apoptotic cells that had not been ingested. The cells were de-
tached with 1% lidocaine (Sigma-Aldrich) in FACS (0.5% BSA/PBS) buffer 
and analyzed by flow cytometry.
Real-time PCR assays. mRNA levels for specific genes were determined 
by real-time PCR in a MX3000P system (Agilent Technologies). Reverse 
transcription was performed using Superscript II RT according to the manu-
facturer’s manual. For each PCR, cDNA template was added to Brilliant 
SYBR  green  QPCR  Master  Mix  (Agilent Technologies)  containing  the 
primer pairs for CCR2 (Forward, 5-AGAGAGCTGCAGCAAAAAGG-3;   
reverse,  5-GGAAAGAGGCAGTTGCAAAG-3),  MCP-1(forward,   
5-AGGTCCCTGTCATGCTTCTG-3; reverse, 5-TCTGGACCCATT-
CCTTCTTG-3), INF- (forward, 5-ACTGGCAAAAGGATGGTGAC-3;   
but also at the functional level via dedicated G protein–
coupled receptor kinases (Vroon et al., 2006). G protein–
coupled receptor kinase (GRK) 2 was reported to phosphorylate 
CCR2, resulting in ligand uncoupling, CCR2 internaliza-
tion, and subsequent loss of CCR2 function (Aragay et al., 
1998). It is of note that Ho et al. (2005) have recently iden-
tified GRK-2 as a downstream target of TGF- that termi-
nates TGF-–induced Smad signaling in a negative-feedback 
mechanism. Thus, we argued that GDF-15 may interfere 
with CCR2 chemotaxis in a GRK-2–dependent manner. 
Exposure of macrophages to GDF-15 for 24 h indeed led to 
a substantial down-regulation of GRK-2 mRNA expression 
in WT macrophages, thereby possibly potentiating CCR2-
dependent migratory responses (Fig. 5 E). Next, we assessed 
GDF-15–induced  macrophage  migration  in  GRK-2+/ 
macrophages. Similar to WT macrophages, MCP-1 also in-
duced migration of GRK-2+/ macrophages (Fig. 5 F). In 
contrast, GDF-15 was unable to induce a significant migra-
tory response in GRK-2+/ cells that have 50% lower GRK-2 
protein expression (Fig. 5 E). Apparently GDF-15–induced 
macrophage migration essentially requires intact GRK-2 
function and thereby possibly modulates CCR2-mediated 
migratory responses.
In conclusion, we are the first to demonstrate that leuko-
cyte deficiency of GDF-15 improves atherosclerotic plaque 
stability by impairing macrophage migration and inducing 
collagen deposition. Our data not only indicate that GDF-15 
and TGF- signaling in macrophages partly overlap but also 
that GDF-15 dampens TGF- function. Next to its modula-
tory effect on TGF- signaling, our studies unveil a novel 
function for GDF-15 in the regulation of CCR2-dependent 
macrophage chemotaxis. Its chemotactic capacity is shown to 
proceed via TGFRII and its downstream effector GRK-2 
and is likely relevant to GDF-15–mediated acute phase re-
sponses. In the context of atherosclerosis, GDF-15 deficiency 
acts protectively by affecting two major processes as it attenu-
ates TGF-1  signaling  and,  more  importantly,  it  amplifies 
CCR2-dependent macrophage migration to and accumula-
tion in the atherosclerotic lesion.
MATERIALS AND METHODS
Animals. LDL receptor (LDLr)/ and CCR2/ mice (on C57BL/6 back-
ground) were obtained from the local animal breeding facility. GDF-15/  
and WT controls were obtained from Johns Hopkins University School   
of Medicine. CCR1/ and CCR5/ mice were obtained from University 
Medical Center Aachen and GRK-2+/ mice were obtained from the Uni-
versity Medical Center Utrecht animal facility. In vivo experiments were 
performed  at  the  animal  facilities  of  the  Gorlaeus  laboratories.  All   
experimental protocols were approved by the ethics committee for animal 
experiments of Leiden University.
Bone marrow transplantation. To induce bone marrow aplasia, male 
LDLr/ recipient mice were exposed to a single dose of 9 Gy (0.19 Gy/
min, 200 kV, 4 mA) total body irradiation using an Andrex Smart 225 
Röntgen source (YXLON International) with a 6-mm aluminum filter 1 d 
before the transplantation. Bone marrow was isolated by flushing the fe-
murs and tibias of GDF-15/ and WT mice with PBS. Subsequently, the 
cell suspension was gently filtered through a 70-µm cell strainer to obtain a 
single cell suspension (BD). Irradiated recipients received 0.5 × 107 bone 224 GDF-15 affects plaque stability | de Jager et al.
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